The aim of this study is to evaluate the pain-relieving effect of a novel chemokine signal-inhibiting compound on allodynia-specific responses in a chronic pain animal model, using our BOLD-fMRI-based pain evaluation system with a green laser. We observed activations in four brain regions related to pain. We found that the compound suppresses green laser-evoked allodynia-specific responses in three regions. We expect that the compound has synergistic pain-relieving effects with existing analgesic agents. Our system is useful to evaluate the effects of new analgesic candidates in non-clinical and, expectantly, clinical studies.